mycophenolate mofetil [CellCept] + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myasthenia Gravis Generalised
Conditions
Myasthenia Gravis Generalised
Trial Timeline
Jun 1, 2004 → Sep 1, 2007
NCT ID
NCT00408213About mycophenolate mofetil [CellCept] + Placebo
mycophenolate mofetil [CellCept] + Placebo is a phase 3 stage product being developed by Roche for Myasthenia Gravis Generalised. The current trial status is completed. This product is registered under clinical trial identifier NCT00408213. Target conditions include Myasthenia Gravis Generalised.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00408213 | Phase 3 | Completed |
Competing Products
20 competing products in Myasthenia Gravis Generalised
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| tacrolimus | Astellas Pharma | Phase 3 | 77 |
| Tacrolimus capsule + Placebo | Astellas Pharma | Phase 3 | 77 |
| tacrolimus + placebo | Astellas Pharma | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Cladribine Low Dose + Cladribine High Dose | Merck | Phase 3 | 77 |
| Remibrutinib (Blinded) + Remibrutinib (Open Label) | Novartis | Phase 3 | 77 |
| Placebo + CFZ533 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| mycophenolate mofetil (CellCept) + placebo | Roche | Phase 3 | 77 |
| inebilizumab + IV Placebo | Amgen | Phase 3 | 76 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Abatacept Injection | Bristol Myers Squibb | Phase 1 | 32 |
| Tolebrutininb + Placebo | Sanofi | Phase 3 | 76 |
| Pozelimab + Cemdisiran + Cemdisiran + Pozelimab | Regeneron Pharmaceuticals | Phase 3 | 76 |
| HIZENTRA ® | CSL | Phase 2 | 51 |
| Subcutaneous immunoglobulins | CSL | Phase 1 | 32 |
| Human normal immunoglobulin G (IgG) | CSL | Phase 3 | 76 |
| zilucoplan (RA101495) | UCB | Phase 3 | 74 |
| zilucoplan (RA101495) + Placebo | UCB | Phase 2 | 49 |